PNC Financial Services Group Inc. Boosts Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

PNC Financial Services Group Inc. boosted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,647 shares of the company’s stock after buying an additional 1,578 shares during the period. PNC Financial Services Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $917,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock valued at $38,487,000 after purchasing an additional 134,705 shares in the last quarter. Financial Sense Advisors Inc. grew its position in shares of Teva Pharmaceutical Industries by 63.5% in the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company’s stock valued at $6,231,000 after purchasing an additional 157,421 shares in the last quarter. King Wealth Management Group grew its position in shares of Teva Pharmaceutical Industries by 1,106.9% in the first quarter. King Wealth Management Group now owns 175,000 shares of the company’s stock valued at $2,690,000 after purchasing an additional 160,500 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Teva Pharmaceutical Industries by 804.7% in the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock valued at $1,037,000 after purchasing an additional 60,016 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 1.2% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company’s stock valued at $404,775,000 after purchasing an additional 300,000 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Bank of America upped their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Truist Financial started coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Buy” and a consensus price target of $24.71.

Teva Pharmaceutical Industries Stock Up 0.3%

NYSE:TEVA opened at $16.41 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The stock’s fifty day moving average is $16.70 and its two-hundred day moving average is $16.32. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The stock has a market capitalization of $18.83 billion, a price-to-earnings ratio of -102.58, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The company had revenue of $4.18 billion for the quarter, compared to analysts’ expectations of $4.34 billion. During the same period in the prior year, the firm earned $0.61 earnings per share. The firm’s revenue was up .3% compared to the same quarter last year. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares in the company, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Placid Jover sold 6,053 shares of the company’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,001 shares of company stock worth $996,958 over the last ninety days. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.